Video

Understanding Supportive Services in Lung Cancer

As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about supportive services for lung cancer.

Related Videos
Image of a man in a suit.
Image of man with black hair.
Image of man with gray hair.
Related Content
"FDA" text.
Published: December 18th 2024 | Updated: December 19th 2024

FDA Approves Ensacove for ALK-Positive NSCLC

Alex Biese
The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
"FDA" text.
December 5th 2024

FDA OKs Imfinzi for Limited-Stage Small Cell Lung Cancer

Darlene Dobkowski, MA
Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of FDA Breakthrough Therapy Designation on a gold background.
December 3rd 2024

FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC

Alex Biese
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations.
Illustration of a person holding a magnifying glass next to paperwork and pills.
December 3rd 2024

Nemvaleukin Shows Manageable Safety Profile in Advanced Solid Tumors

Ashley Chan
In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.